| Display title | Chemistry:Methenmadinone caproate |
| Default sort key | Methenmadinone caproate |
| Page length (in bytes) | 5,995 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 324372 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Page image |  |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>WikiEd2 |
| Date of page creation | 23:26, 5 February 2024 |
| Latest editor | imported>WikiEd2 |
| Date of latest edit | 23:26, 5 February 2024 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Methenmadinone caproate (MMC, also known as superlutin caproate) is a progestin medication which was developed in Czechoslovakia in the 1960s and was studied for potential use in combined injectable contraceptives in the 1970s but was never marketed. It was studied as a combined injectable contraceptive... |
